Specificity of the Autologous Neutralizing Antibody Response

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2010 Jan 6

PMID 20048698

Citations 49

Authors

Penny L Moore

Elin S Gray

Lynn Morris

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: It has long been known that autologous neutralizing antibodies (AnAbs) exert pressure on the envelope of HIV, resulting in neutralization escape. However, recently, progress has been made in uncovering the precise targets of these potent early antibodies.

Recent Findings: AnAbs primarily target variable regions of the HIV-1 envelope, explaining the strain-specificity of these antibodies. Despite high neutralizing potential and cross-reactivity, anti-V3 antibodies do not contribute to autologous neutralization. The V1V2 is commonly immunogenic in early HIV-1 and simian human immunodeficiency virus infections, though the nature of these epitopes remains to be determined. In subtype C viruses, the C3 region is a neutralization target, possibly as a result of its more exposed and amphipathic structure. Autologous neutralization appears to be mediated by very few AnAb specificities that develop sequentially suggesting the possibility of immunological hierarchies for both binding and neutralizing antibodies. The role of AnAbs in preventing superinfection and in restricting virus replication is reexamined in the context of recent data.

Summary: New studies have greatly contributed toward our understanding of the specificities mediating autologous neutralization and highlighted potential vulnerabilities on transmitted viruses. However, the contribution of AnAbs to the development of neutralization breadth remains to be characterized.

Citing Articles

Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.

Becerra J, Hitchcock L, Vu K, Gach J Microb Cell. 2024; 11:207-220.

PMID: 38975023 PMC: 11224682. DOI: 10.15698/mic2024.07.826.

Assessing immunogenicity barriers of the HIV-1 envelope trimer.

Maliqi L, Friedrich N, Glogl M, Schmutz S, Schmidt D, Rusert P NPJ Vaccines. 2023; 8(1):148.

PMID: 37777519 PMC: 10542815. DOI: 10.1038/s41541-023-00746-3.

Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption.

Esmaeilzadeh E, Etemad B, Lavine C, Garneau L, Li Y, Regan J Sci Transl Med. 2023; 15(695):eabq4490.

PMID: 37163616 PMC: 10576978. DOI: 10.1126/scitranslmed.abq4490.

Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.

Kuriakose Gift S, Wieczorek L, Sanders-Buell E, Zemil M, Molnar S, Donofrio G J Virol. 2023; 97(2):e0163522.

PMID: 36749076 PMC: 9973046. DOI: 10.1128/jvi.01635-22.

Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression.

Valenzuela-Fernandez A, Cabrera-Rodriguez R, Casado C, Perez-Yanes S, Pernas M, Garcia-Luis J Biomedicines. 2022; 10(9).

PMID: 36140273 PMC: 9495913. DOI: 10.3390/biomedicines10092172.

References

Davis K, Gray E, Moore P, Decker J, Salomon A, Montefiori D . High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009; 387(2):414-26. PMC: 2792036. DOI: 10.1016/j.virol.2009.02.022. View

Salazar-Gonzalez J, Bailes E, Pham K, Salazar M, Guffey M, Keele B . Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008; 82(8):3952-70. PMC: 2293010. DOI: 10.1128/JVI.02660-07. View

Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, NYSTROM G . Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 1990; 4(2):107-12. DOI: 10.1097/00002030-199002000-00002. View

Binley J, Wrin T, Korber B, Zwick M, Wang M, Chappey C . Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004; 78(23):13232-52. PMC: 524984. DOI: 10.1128/JVI.78.23.13232-13252.2004. View

Shen L, Peterson S, Sedaghat A, McMahon M, Callender M, Zhang H . Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008; 14(7):762-6. PMC: 2743464. DOI: 10.1038/nm1777. View

Krachmarov C, Pinter A, Honnen W, Gorny M, Nyambi P, Zolla-Pazner S . Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol. 2004; 79(2):780-90. PMC: 538589. DOI: 10.1128/JVI.79.2.780-790.2005. View

Arendrup M, Nielsen C, Hansen J, Pedersen C, Mathiesen L, Nielsen J . Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr (1988). 1992; 5(3):303-7. View

McKeating J, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N . Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol. 1993; 67(8):4932-44. PMC: 237881. DOI: 10.1128/JVI.67.8.4932-4944.1993. View

Binley J, Lybarger E, Crooks E, Seaman M, Gray E, Davis K . Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008; 82(23):11651-68. PMC: 2583680. DOI: 10.1128/JVI.01762-08. View

10.

Gorny M, Stamatatos L, Volsky B, Revesz K, Williams C, Wang X . Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005; 79(8):5232-7. PMC: 1069558. DOI: 10.1128/JVI.79.8.5232-5237.2005. View

11.

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

12.

Kulkarni S, Lapedes A, Tang H, Gnanakaran S, Daniels M, Zhang M . Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology. 2009; 385(2):505-20. PMC: 2677301. DOI: 10.1016/j.virol.2008.12.032. View

13.

Dhillon A, Donners H, Pantophlet R, Johnson W, Decker J, Shaw G . Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol. 2007; 81(12):6548-62. PMC: 1900098. DOI: 10.1128/JVI.02749-06. View

14.

Gray E, Moore P, Bibollet-Ruche F, Li H, Decker J, Meyers T . 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2007; 82(5):2367-75. PMC: 2258954. DOI: 10.1128/JVI.02161-07. View

15.

Li M, Salazar-Gonzalez J, Derdeyn C, Morris L, Williamson C, Robinson J . Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006; 80(23):11776-90. PMC: 1642599. DOI: 10.1128/JVI.01730-06. View

16.

Guan Y, Sajadi M, Kamin-Lewis R, Fouts T, Dimitrov A, Zhang Z . Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A. 2009; 106(10):3952-7. PMC: 2644653. DOI: 10.1073/pnas.0813392106. View

17.

Scheid J, Mouquet H, Feldhahn N, Walker B, Pereyra F, Cutrell E . A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2008; 343(2):65-7. PMC: 2754789. DOI: 10.1016/j.jim.2008.11.012. View

18.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D . Diversity considerations in HIV-1 vaccine selection. Science. 2002; 296(5577):2354-60. DOI: 10.1126/science.1070441. View

19.

Wu L, Yang Z, Xu L, Welcher B, Winfrey S, Shao Y . Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine. 2006; 24(23):4995-5002. DOI: 10.1016/j.vaccine.2006.03.083. View

20.

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View